For both melanoma cell lines, treatment with protein kinase inhibitors was accompanied by a decrease in proliferation: highest after the use of the AKT inhibitor - MK2206 (about 40%), and slightly smaller for inhibitors of the MAP kinase pathway, AS-703026 or U126 (Fig. 3b). This evidence concerns the gene AKT1 and melanoma.